- Stocks
- Healthcare
- NASDAQ: ORGO

Price (delayed)

$16.51

Market cap

$2.12B

P/E Ratio

40.27

Dividend/share

N/A

EPS

$0.41

Enterprise value

$2.14B

The EPS has surged by 195% year-on-year and by 141% since the previous quarter

The net income has soared by 146% from the previous quarter

The quick ratio has grown by 39% year-on-year but it has declined by 2.4% since the previous quarter

ORGO's debt is up by 17% since the previous quarter but it is down by 10% year-on-year

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.organogenesis.com

What are the main financial stats of ORGO

Market
Valuations
Earnings

Shares outstanding

128.22M

Market cap

$2.12B

Enterprise value

$2.14B

Price to earnings (P/E)

40.27

Price to book (P/B)

13.43

Price to sales (P/S)

5.57

EV/EBIT

38.09

EV/EBITDA

32.76

EV/Sales

5.64

Revenue

$379.12M

EBIT

$56.14M

EBITDA

$65.27M

Free cash flow

$746,000

Per share
Balance sheet
Liquidity

EPS

$0.41

Free cash flow per share

$0.01

Book value per share

$1.23

Revenue per share

$2.96

TBVPS

$2.04

Total assets

$319.18M

Total liabilities

$161.89M

Debt

$99.17M

Equity

$157.29M

Working capital

$111.23M

Debt to equity

0.63

Current ratio

2.5

Quick ratio

2.03

Net debt/EBITDA

0.33

Margins
Efficiency
Dividend

EBITDA margin

17.2%

Gross margin

75.2%

Net margin

11.7%

Operating margin

14.6%

Return on assets

16.4%

Return on equity

43.7%

Return on invested capital

29.8%

Return on capital employed

22.9%

Return on sales

14.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Organogenesis Holdings stock price performed over time

Intraday

-1.43%

1 week

9.19%

1 month

-0.9%

1 year

332.2%

YTD

119.26%

QTD

-9.39%

How have Organogenesis Holdings's revenue and profit performed over time

Revenue

$379.12M

Gross profit

$285.1M

Operating income

$55.19M

Net income

$44.21M

Gross margin

75.2%

Net margin

11.7%

ORGO's net margin has soared by 175% year-on-year and by 121% since the previous quarter

The net income has soared by 146% from the previous quarter

Organogenesis Holdings's operating income has soared by 101% from the previous quarter

Organogenesis Holdings's operating margin has surged by 80% QoQ

What is Organogenesis Holdings's growth rate over time

What is Organogenesis Holdings stock price valuation

P/E

40.27

P/B

13.43

P/S

5.57

EV/EBIT

38.09

EV/EBITDA

32.76

EV/Sales

5.64

The EPS has surged by 195% year-on-year and by 141% since the previous quarter

The P/B is 66% below the 5-year quarterly average of 39.1 but 41% above the last 4 quarters average of 9.5

ORGO's equity is up by 8% QoQ

ORGO's P/S is 142% above its 5-year quarterly average of 2.3 and 99% above its last 4 quarters average of 2.8

The company's revenue rose by 43% YoY and by 12% QoQ

How efficient is Organogenesis Holdings business performance

The ROA has soared by 176% YoY and by 122% from the previous quarter

Organogenesis Holdings's return on equity has surged by 135% YoY and by 75% QoQ

The return on invested capital has surged by 80% since the previous quarter

The return on sales has surged by 68% since the previous quarter

What is ORGO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ORGO.

How did Organogenesis Holdings financials performed over time

ORGO's total assets is 97% greater than its total liabilities

ORGO's total assets has surged by 53% year-on-year and by 8% since the previous quarter

The quick ratio has grown by 39% year-on-year but it has declined by 2.4% since the previous quarter

ORGO's debt is 37% smaller than its equity

The debt to equity has dropped by 77% year-on-year but it is up by 9% since the previous quarter

ORGO's debt is up by 17% since the previous quarter but it is down by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.